Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia
A Study of T-Cell Replete, HLA-Mismatched Haploidentical Bone Marrow Transplantation With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Lacking HLA-Matched Related Donor
Severe aplastic anemia is a rare and serious form of bone marrow failure related to an immune-mediated mechanism that results in severe pancytopenia and high risk for infections and bleeding. Patients with matched sibling donors for transplantation have a 80-90% chance of survival; however, a response rate with just immunosuppression for those patients lacking suitable HLA-matched related siblings is only 60%. With immunosuppression, only 1/3 of patients are cured, 1/3 are dependent on long term immunosuppression, and the other 1/3 relapse or develop a clonal disorder. Recent studies have shown that using a haploidentical donor for transplantation has good response rates and significantly lower rates of acute and chronic GVHD.
Mismatched haploidentical donors will be identified for patients with severe aplastic anemia. These patients will undergo a preparative regimen of Fludarabine/Cyclophosphamide/TBI followed by haploidentical bone marrow transplantation. Post-transplant Cyclophosphamide will be administered on Days 3 & 4. Immunosuppression with Tacrolimus and MMF will begin on Day +5; MMF will be discontinued on Day +35 while Tacrolimus continues until Day +180. Investigators hypothesize that haploidentical transplantation with the above-mentioned preparative regimen will have a <30% graft failure rate. The one-sided exact Binomial test at 5% significance level will be used to test this hypothesis. The size of 20 patients provides the power of 92.5% for confirming the 30-day graft failure rate <30%.
Demonstrate sustained engraftment after T-cell replete HLA-mismatched haploidentical bone marrow transplantation by collecting chimerism tests monthly following transplant
Determine the incidence of regimen-related mortality at 100 days post transplantation by recording treatment-related adverse events
Severe Aplastic Anemia
Study Arms / Comparison Groups
Description: Fludarabine, Cyclophosphamide, TBI followed by bone marrow transplantation. Post-transplant Cyclophosphamide will be on Days 3 & 4.
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
September 9, 2016
August 31, 2026
Primary Completion Date
August 31, 2025
Inclusion Criteria: - Availability of 3/6 - 5/6 matched (HLA-A, B, DR) related donor who must have negative HLA cross-match in the host vs. graft direction - Age <= 65 years for previously treated and <= 75 years for previously treated patients - KPS >= 70% - Aplastic Anemia that meets the following criteria: Peripheral Blood (must fulfill 2 of 3): - <500 PMN/mm3 - <20,000 platelets - absolute reticulocyte count <40,000/microL Bone Marrow (must be either): - markedly hypocellular (<25% of normal cellularity) - moderately hypocellular with 70% non-myeloid precursors and patient meets peripheral blood criteria above Exclusion Criteria: - poor cardiac function (LVEF <40%) - poor pulmonary function (FEV1 & FVC <50% predicted) - poor liver function (bili >= 2mg/dL) - poor renal function (creatinine >= 2.0mg/dL or creatinine clearance <40mL/min) - prior allogeneic transplant
1 Year - 75 Years
Accepts Healthy Volunteers
Melhem Solh, MD, 404-255-1930, [email protected]
Northside Hospital, Inc.
Melhem Solh, MD, Principal Investigator, Blood and Marrow Transplant Group of Georgia